In this use case, find out how MMIT, using NorstellaLinQ, used real-world data to help a manufacturer specializing in multiple myeloma therapies get a clearer picture of high-risk patients and the physicians treating them.
Identify newly diagnosed and relapsed high-risk patients using genomic and EMR data.
Improve outreach to healthcare providers likely to treat these specific patient populations.
Generate actionable alerts to engage HCPs and guide critical treatment conversations.
Reducing Risk: 5 Steps for a Fearless Launch